Nitroglycerin plus clopidogrel for acute myocardial infarction and the effect on cardiac function indices

To evaluate the efficacy of nitroglycerin plus clopidogrel for acute myocardial infarction and the effect on the cardiac function indices. From April 2019 to April 2020, 90 patients with acute myocardial infarction enrolled in our hospital were recruited and assigned to receive either oral clopidogrel (control group) or nitroglycerin plus clopidogrel (experimental group), with 45 cases in each group. Outcome measures included clinical efficacy, inflammatory factors, cardiac function indices, myocardial enzymatic indexes, Selvester QRS score, myocardial infarction area and quality of life. Nitroglycerin plus clopidogrel resulted in significantly higher treatment efficiency versus clopidogrel alone (P<0.05). Patients with nitroglycerin plus clopidogrel showed significantly reduced levels of inflammatory factors, a lower ST reduction and a lower end-systolic volume index (ESVI) versus those with single clopidogrel (P<0.05). Nitroglycerin plus clopidogrel was associated with a shorter prothrombin time, higher end-diastolic volume index (EDVI) and SF-36 scores and lower myocardial enzymatic indexes and QRS scores versus clopidogrel (P<0.05). Patients with combined therapy had a smaller myocardial infarction area than those with monotherapy (P<0.05). Nitroglycerin plus clopidogrel ameliorates the cardiac function indices of patients with acute myocardial infarction, mitigates the inflammatory responses, and improves the patient's quality of life. Further research is required prior to clinical promotion.